Asia Pac Compliance Code and APEC Principles and Nanjing Declaration Updates - Healthier China Through Innovation

Henry Li, General Counsel, RDPAC
Beijing, China
About **RDPAC**: R&D based Pharmaceutical Association Committee

The conditions for membership are:

- the company is a R&D-based pharmaceutical company;
- the company has substantial business operations in China;
- the company has agreed to the RDPAC Code of Practice.

**Milestones**

- 1995 – the R&D based pharmaceutical association was organized;
- 1999 – Beijing Rep Office was established;
- 2005 – RDPAC was formally incorporated.
### 38 Member Companies

#### EU (20)
- AstraZeneca
- Bayer HealthCare
- Boehringer Ingelheim
- Chiesi
- Fresenius Kabi
- Gedeon Richter Plc.
- Helsinn
- Ipsen
- LEO Pharma
- Lundbeck
- Menarini
- Merck Serono
- Mundipharma
- Novartis
- Novo Nordisk
- Roche
- Sanofi Aventis
- Servier
- UCB
- Zambon

#### US (12)
- Abbott
- AbbVie
- Allergan
- Amgen
- Baxter
- Bristol-Myers Squibb
- Celgene
- Eli Lilly
- GE Healthcare
- MSD
- Pfizer
- Xian-Janssen

#### JP (6)
- Astellas
- Chugai
- Eisai
- Kyowa Kirin
- Sumitomo
- Takeda
RDPAC in China

38 member companies, 49 plants, 31 R&D centers. In the last five years, RDPAC members have introduced at least 67 innovative drugs for the benefit of Chinese patients, representing over 80% of all innovative drugs introduced to China during this period.

Data updated: 2015
## Worldwide Federation of RDPAC

<table>
<thead>
<tr>
<th></th>
<th>International Federation of Pharmaceutical Manufacturers &amp; Associations (IFPMA)</th>
<th>国际制药企业协会联盟 (RDPAC系IFPMA会员)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>European Federation of Pharmaceutical Industries and Associations (EFPIA)</td>
<td>欧洲制药企业协会联盟</td>
</tr>
<tr>
<td>3</td>
<td>Pharmaceutical Research and Manufacturers of America (PhRMA)</td>
<td>美国药品研发与制造企业协会</td>
</tr>
<tr>
<td>4</td>
<td>Japan Pharmaceutical Manufacturers Association (JPMA)</td>
<td>日本制药企业协会</td>
</tr>
</tbody>
</table>
RDPAC rigorously promotes ethical business practice

- RDPAC Code of Practice
- Medical Rep Certification (MRC) Program
RDPAC Code of Practice 2012 and 2015
RDPAC keeps on devoting itself to ensure promotional behaviors match high ethical standards

- Sponsorship to an overseas meeting must fulfill the new principle of IFPMA;
- Prohibit to sponsor individual HCPs;
- Prohibit payment in cash (transfer through company bank account);
- Prohibit collecting patient's case or prescription data via HCPs;
- More control on speaker fee to HCPs (contract; to monitor “high risk” speakers, etc.)
- Prohibit cultural gift.

- Enlarge the applicable scope of the Code;
- Added several provisions on transparency;
- Further emphasize and explicit the prohibition of any form of entertainment.

1999

2nd edition of Code of Practice

2002

3rd version RDPAC Code follow IFPMA Code
- Minimum level of criterion and principle of global industry;
- Specify the scope and enumerate non applicable situation;
- Explicit the basic principle of promotion behavior;
- Roll out the Medical Reps training.

2006

5th edition of RDPAC Code
- Enlarge the scope to the interaction activities between Pharmaceutical enterprises and HCPs, HCOs and patient orgs.

2010

2012

2015

In the process of updating RDPAC Code of Practice 2015

2016
RDPAC's MRC Program

- There are an estimated 70,000 Medical Reps in RDPAC member companies.
- There are 2,000,000 Medical Reps in China, according to estimation by the magazine “Economist”
In 2015 MR officially listed in China's “Occupation Encyclopedia”

- **Occupation name:**
  Medical Representatives

- **Occupation definition:**
  Professionals representing pharmaceutical enterprises in delivering, communicating and providing feedbacks on information of medicines.

  *Very much in line with international standard!*
RDPAC's MRC Program

- 2003: Training materials preparation
- 2005: Pilot trials in Beijing – 9 members, 226 MRs
- 2007: Roll-out to all members companies
- 2007: in January first batch of MR Certificates were issued
- 2012: MRC Renewal System was launched
- 2014: Improved MRC system’s capability
- 2016: plan on expanding MRC to other local pharmaceutical associations
# MRC Training Manual

--- the Code of practice part is the most important one

### Volume 1. Medical Basics
- Chapter 1 Human Body
- Chapter 2 Pathology and immunity
- Chapter 3 Nervous System
- Chapter 4 Circulation System
- Chapter 5 Respiratory System
- Chapter 6 Muscle-Skeletal System
- Chapter 7 Digestive System
- Chapter 8 Urological System
- Chapter 9 Endocrine System
- Chapter 10 Genitor System
- Chapter 11 Dermatological
- Chapter 12 Sensory Organs

### Volume 2. Pharmaceutical Basics
- Chapter 1 Pharmacology
- Chapter 2 Clinical Pharmacology
- Chapter 3 Pharmacy
- Chapter 4 Monitoring of Adverse Drug Reaction

### Volume 3. Code of Pharmaceutical Marketing Practices

### Volume 4. Industry Overview
- Chapter 1 Healthcare overview in China
- Chapter 2 Current organization and operation of healthcare players in China
- Chapter 3 Drug market worldwide

### Attachments
- Examination Syllabus
- Test questions answers
- Laws related to Medicine industry
- Mexico City Principles

---

Developed the on-line course ware on e-learning platform: [http://e-training.rdpacmrc.org](http://e-training.rdpacmrc.org)
RDPAC collaborated closely with domestic and international partners on promotion of ethical business practice
Industry Alignment – 2015 China Forum of Pharma Enterprises on Ethical Business Practice

17 associations:

- CPIA
- CCCMHPIE
- Sino-PHIRDA
- RDPAC
- CATCM
- CNMA
- CAPC
- CPEP
- CRAECC
- CMP
- CAMDI
- CNPPA
- CMEA
- CPEA
- CPAPE
- CMBA
- CQAP

9 Initiators

8 newly joined
Effort aiming at developing a national MRC system in China
- Forum on EBP of Pharma Enterprises on June 28, 2016 in Beijing

- Signed a MOU among four key pharmaceutical associations in China - CPIA (China Pharmaceutical Industry Association), CATCM (China Association of Traditional Chinese Medicine) and CPEP (China Pharmaceutical Enterprises Promotion)
- Aim at, among others, deepening the alignment by these associations in China on MR occupation management and promotion in China and EBP of MRs.